Climb Bio, Inc.

Report azionario NasdaqGM:CLYM

Capitalizzazione di mercato: US$995.9m

Climb Bio Crescita futura

Criteri Future verificati 2/6

Si prevede che gli utili di Climb Bio diminuiranno del 28.8% all'anno, mentre si prevede che il fatturato annuo crescerà del 81.2% all'anno. Si prevede che l'EPS diminuirà del 22.1% all'anno.

Informazioni chiave

-28.8%

Tasso di crescita degli utili

-22.10%

Tasso di crescita dell'EPS

Biotechs crescita degli utili27.2%
Tasso di crescita dei ricavi81.2%
Rendimento futuro del capitale proprion/a
Copertura analitica

Good

Ultimo aggiornamento19 Aug 2026

Aggiornamenti recenti sulla crescita futura

Recent updates

Articolo di analisi • Aug 08

Climb Bio (NASDAQ:CLYM) Is In A Good Position To Deliver On Growth Plans

Just because a business does not make any money, does not mean that the stock will go down. By way of example, Climb...
Seeking Alpha • Jul 23

Climb Bio: Three Key Kidney Disease Readouts In Q4 Ought To Generate Volatility

Summary Climb Bio has surged >160% YTD, driven by anticipation for pivotal Phase 2/1b data in pMN, ITP, and SLE due by year-end 2026. Budoprutug, a CD19-targeting monoclonal antibody, has shown promising early safety and efficacy signals across multiple autoimmune indications, with Fast Track status in pMN. CLYM’s strong cash position ($146.3m, no significant debt) supports operations into 2028, but future Phase 3 trials will likely require dilutive capital raises. Upcoming data readouts are high-stakes; positive results could drive further upside, while underwhelming data may cause the stock to lose up to half its value. Read the full article on Seeking Alpha
Articolo di analisi • Feb 07

Here's Why We're Watching Climb Bio's (NASDAQ:CLYM) Cash Burn Situation

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Seeking Alpha • Sep 23

Eliem Therapeutics: Recent Strategic Pipeline Restructuring

Summary Eliem Therapeutics, founded in 2019, shifted focus to autoimmune diseases with the acquisition of Tenet Medicines and its lead molecule, budoprutug. Budoprutug targets CD19-positive B cells, aiming to treat SLE, ITP, and MN by reducing pathogenic autoantibodies and improving disease symptoms. Early clinical trials for MN showed promising results, with 60% of patients achieving complete remission of proteinuria, supporting further development. Despite a decent market cap and cash reserves, ELYM's early-stage status and single-molecule focus make it a cautious watch rather than an immediate investment. Read the full article on Seeking Alpha
Seeking Alpha • Jun 28

Eliem Therapeutics: Year End 2024 MN Data With Further Potential To Unlock Value

Summary Results from Eliem Therapeutics, Inc.'s phase 1b study, using TNT119 for the treatment of patients with membranous nephropathy, expected by the end of 2024. It is expected that the global membranous nephropathy treatment market could reach $328.4 million by 2034. Two other large market indications that can be targeted using TNT119 are systemic lupus erythematosus and immune thrombocytopenia. Acquisition of Tenet Medicines and $120 million private placement agreement provide funding for operations into 2027, with cash on hand at $220 million. Read the full article on Seeking Alpha
Articolo di analisi • Feb 01

Here's Why We're Not Too Worried About Eliem Therapeutics' (NASDAQ:ELYM) Cash Burn Situation

Just because a business does not make any money, does not mean that the stock will go down. For example, although...
Articolo di analisi • Jun 24

We Think Eliem Therapeutics (NASDAQ:ELYM) Needs To Drive Business Growth Carefully

We can readily understand why investors are attracted to unprofitable companies. For example, although...
Articolo di analisi • Mar 08

We're Not Very Worried About Eliem Therapeutics' (NASDAQ:ELYM) Cash Burn Rate

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com...
Articolo di analisi • Nov 18

We're Not Very Worried About Eliem Therapeutics' (NASDAQ:ELYM) Cash Burn Rate

We can readily understand why investors are attracted to unprofitable companies. For example, although...
Seeking Alpha • Aug 15

Eliem Therapeutics GAAP EPS of -$0.56 misses by $0.09

Eliem Therapeutics press release (NASDAQ:ELYM): Q2 GAAP EPS of -$0.56 misses by $0.09. Cash, cash equivalents and short- and long-term marketable securities was $134.7M as of June 30, 2022, as compared to $161.4M as of December 31, 2021. With the discontinuation of ETX-810, the company’s current cash, cash equivalents and short- and long-term marketable securities are now expected to fund operations into 2025.
Seeking Alpha • Aug 02

Eliem to discontinue development of lead asset as mid-stage pain trial fails

Clinical-stage biotech Eliem Therapeutics (NASDAQ:ELYM) announced on Tuesday that the company decided to discontinue further development of its lead asset ETX-810 after the failure of a mid-stage trial for the candidate in lumbosacral radicular pain (LSRP). The primary endpoint of the 148-patient Phase 2a trial was the change in the weekly average of the daily pain score from baseline to week 4, measured using the Pain Intensity Numerical Rating Scale (PI-NRS). The results indicated that ETX-810 did not indicate a statistically significant separation from the placebo in the primary endpoint, according to the company. The results were similar to previously disclosed data from another Phase 2 trial in diabetic peripheral neuropathic pain (DPNP) which also indicated a lack of separation for the treatment arm compared to the placebo, the company said.
Seeking Alpha • Jul 11

SVB Leerink cuts PT on Eliem Therapeutics, reaffirms Outperform rating

SVB Leerink on Monday cut its price target on Eliem Therapeutics (NASDAQ:ELYM) to $9 from $13. The new PT - based on an SOTP analysis that forecasts cash flows into early 2040s, with 11% discount rate - implies potential upside of 142.6% to ELYM's last close. The brokerage reiterated its Outperform rating, in-line with sell-side rating of Strong Buy. "Given the decreased bioavailability of ETX-155 observed in the phase 1b interim data readout in photosensitive epilepsy, we lowered our POS for all ETX-155 programs, which resulted in our PT moving to $9," analyst Marc Goodman wrote in a note to clients. "We still expect data from ETX-810 in lumbosacral radicular pain in Q3, although expectations are low after the failed phase 2 study in diabetic peripheral neuropathy," he added. ELYM stock, which fell as much as 5.4% on Monday, has declined 67.3% YTD.

Previsioni di crescita degli utili e dei ricavi

NasdaqGM:CLYM - Stime future degli analisti e dati finanziari passati (USD Millions )
DataRicaviUtiliFlusso di cassa liberoLiquidità dell'operazioneAvg. Numero di analisti
12/31/20281-129-126-10912
12/31/20271-83-58-7314
12/31/2026N/A-60-60-5815
6/30/2026N/A-58-53-53N/A
3/31/2026N/A-53-53-53N/A
12/31/2025N/A-60-55-54N/A
9/30/2025N/A-51-44-44N/A
6/30/2025N/A-47-40-40N/A
3/31/2025N/A-93-29-29N/A
12/31/2024N/A-74-16-16N/A
9/30/2024N/A-69-11-11N/A
6/30/2024N/A-6400N/A
3/31/2024N/A-15-7-7N/A
12/31/2023N/A-35-21-21N/A
9/30/2023N/A-39-28-28N/A
6/30/2023N/A-45-36-36N/A
3/31/2023N/A-54-42-42N/A
12/31/2022N/A-45-37-37N/A
9/30/2022N/A-48-37-37N/A
6/30/2022N/A-49-46-46N/A
3/31/2022N/A-46-40-40N/A
12/31/2021N/A-52-36-36N/A
9/30/2021N/A-57-34-34N/A
6/30/2021N/A-49-23-23N/A
3/31/2021N/A-40-19-19N/A
12/31/2020N/A-23-14-14N/A

Previsioni di crescita futura degli analisti

Guadagni vs tasso di risparmio: Si prevede che CLYM rimarrà non redditizia nei prossimi 3 anni.

Guadagni vs Mercato: Si prevede che CLYM rimarrà non redditizia nei prossimi 3 anni.

Guadagni ad alta crescita: Si prevede che CLYM rimarrà non redditizia nei prossimi 3 anni.

Ricavi vs Mercato: Si prevede che il fatturato di CLYM ( 81.2% all'anno) crescerà più rapidamente del mercato US ( 12.9% all'anno).

Ricavi ad alta crescita: Si prevede che il fatturato di CLYM ( 81.2% all'anno) crescerà più rapidamente di 20% all'anno.

Previsioni di crescita dell'utile per azione

Rendimento futuro del capitale proprio

ROE futuro: Dati insufficienti per determinare se il Return on Equity di CLYM è previsto essere elevato tra 3 anni

Scoprire le aziende in crescita

7D

1Y

7D

1Y

7D

1Y

Analisi aziendale e situazione dei dati finanziari

DatiUltimo aggiornamento (ora UTC)
Analisi dell'azienda2026/08/20 23:35
Prezzo dell'azione a fine giornata2026/08/20 00:00
Utili2026/06/30
Utili annuali2025/12/31

Fonti dei dati

I dati utilizzati nella nostra analisi aziendale provengono da S&P Global Market Intelligence LLC. I seguenti dati sono utilizzati nel nostro modello di analisi per generare questo report. I dati sono normalizzati, il che può comportare un ritardo nella disponibilità della fonte.

PacchettoDatiTempisticaEsempio Fonte USA *
Dati finanziari della società10 anni
  • Conto economico
  • Rendiconto finanziario
  • Bilancio
Stime di consenso degli analisti+3 anni
  • Previsioni finanziarie
  • Obiettivi di prezzo degli analisti
Prezzi di mercato30 anni
  • Prezzi delle azioni
  • Dividendi, scissioni e azioni
Proprietà10 anni
  • Top azionisti
  • Insider trading
Gestione10 anni
  • Team di leadership
  • Consiglio di amministrazione
Sviluppi principali10 anni
  • Annunci aziendali

* Esempio per i titoli statunitensi, per i titoli non statunitensi si utilizzano forme e fonti normative equivalenti.

Se non specificato, tutti i dati finanziari si basano su un periodo annuale ma vengono aggiornati trimestralmente. Si tratta dei cosiddetti dati TTM (Trailing Twelve Month) o LTM (Last Twelve Month). Per saperne di più.

Modello di analisi e Snowflake

I dettagli del modello di analisi utilizzato per generare questo report sono disponibili sulla nostra pagina GitHub; abbiamo anche delle guide su come utilizzare i nostri report e dei tutorial su YouTube.

Scoprite il team di livello mondiale che ha progettato e realizzato il modello di analisi Simply Wall St.

Metriche di settore e industriali

Le nostre metriche di settore e di sezione sono calcolate ogni 6 ore da Simply Wall St; i dettagli del nostro processo sono disponibili su Github.

Fonti analitiche

Climb Bio, Inc. è coperta da 18 analisti. 15 di questi analisti ha fornito le stime di fatturato o di utile utilizzate come input per il nostro report. Le stime degli analisti vengono aggiornate nel corso della giornata.

AnalistaIstituzione
Colleen KusyBaird
null nullBaird
Mayank MamtaniB. Riley Securities, Inc.